…A majority of patients with psychiatric comorbidities secondary to tuberous sclerosis complex (TSC) respond to psychoactive medications, according to a single-centre analysis of clinical records (Chung et al. Ann Clin Psychiatry 2011; 23: 263-269). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
Two novel compounds currently in development – bapineuzumab and solanezumab – for the treatment of Alzheimer’s disease expect to release phase III data in 2012. Those results may usher in a new era, or may add names to the list of high-profile setbacks in AD therapeutics such as tarenflurbil (Myriad), semagacestat (Lilly/Elan), tramiprosate (Neurochem) and AN1792 (Elan). Subscribe to read more It takes 30 seconds or login using your email address…
…HE AMERICAN EPILEPSY SOCIETY 65TH ANNUAL MEETING, BALTIMORE, MD, DECEMBER 2-6, 2011 – A Norwegian study estimates that the risk of sudden unexpected death in epilepsy (SUDEP) is 2.5 per 1000 patient-years in female patients receiving lamotrigine compared to 0.5 per 1000 patient-years in women not on lamotrigine (Aurlien et al. AES 2011; abstract 3.205). Subscribe to read more It takes 30 seconds or login using your email address Please enter the e…
…istered the newsletter with Continue…
…Retigabine (ezogabine in the U.S.), which activates KCNQ2/2 potassium channels, is effective as an adjunctive treatment in partial-onset seizures, according to the results of the phase III RESTORE 1 trial (French et al. Neurology 2011; 76: 1555-1563). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…